Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder

November 25, 2024 01:13 PM PST | By EIN Presswire

Google News:

Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder — Image source: EIN Presswire

Recent News

Estée Lauder (NYSE:EL) Stock Gains As Leadership Strategy NYSE Composi...

Oceaneering International Earnings Growth Shows Positive Signs for (NY...

JPMorgan (NYSE:JPM) Chase Fixed Strengthen Experience Dow Jones Indust...

Realty Strengthens (NYSE:O) Financial Position NYSE Composite

SAN JOSE, CA, UNITED STATES, November 25, 2024 /EINPresswire.com/ -- Biomed Industries, Inc. (Biomed) announced today that its CEO, Dr. Lloyd Tran, presented groundbreaking research on the company’s investigational drug, NA-931, during the keynote address at the 6th World Conference on Addiction Medicine and Psychiatry, held November 25–26 in Paris, France.

The conference, themed "Exploring Innovative Ideas and Remedy Solutions for Addictive Disorders," gathers global experts to discuss advancements in addiction medicine and psychiatry.

Dr. Tran’s keynote, titled “NA-931: A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Attenuates Alcohol-Mediated Behavior,” showcased preclinical data on NA-931. Originally developed for metabolic disorders such as obesity, the research highlights its potential for treating Alcohol Use Disorder (AUD).

Preclinical studies demonstrate that NA-931 significantly attenuates alcohol-induced locomotor stimulation while reducing alcohol intake and alcohol-seeking behaviors in animal models. These results position NA-931 as a promising therapeutic candidate for AUD.

A key advantage of NA-931 is its oral formulation, which offers a more favorable safety profile compared to existing GLP-1-based therapies.

“Our research underscores NA-931’s transformative potential as a therapy for Alcohol Use Disorder,” said Dr. Tran. “Our findings reveal that NA-931, a quadruple IGF-1/GLP-1/GIP/Glucagon receptor agonist, mitigates the effects of alcohol, expanding its therapeutics beyond glucose regulation and obesity treatment.”

According to the 2023 National Survey on Drug Use and Health (NSDUH), 28.9 million Americans aged 12 and older experienced AUD. Globally, the World Health Organization estimates that AUD affects 400 million people, representing approximately 7% of the population aged 15 and older.

The AUD treatment market reflects the significant growth seen in the obesity drug market. In 2017, the global obesity market was valued at $1.3 billion. Following the introduction of GLP-1-based weight loss therapies, the market is projected to surpass $100 billion in the next five years. Similarly, the AUD drug market, valued at $667 million in 2023, presents immense growth potential as innovative treatments like NA-931 advance.

About Biomed Industries, Inc.
Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to address critical unmet medical needs. Its research portfolio includes treatments for Alzheimer’s disease, Major Depressive Disorder (MDD), diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), stroke, rare diseases such as Rett Syndrome and Fragile X, and Alcohol Use Disorder.

For more information, please visit Biomed’s website: https://www.biomedind.com/

Media Contact
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131, USA
Tel: 800-824-5135
Email: [email protected]

Dr. Lloyd L. Tran
Biomed Industries, Inc.
+1 800-824-5135
email us here
Visit us on social media:
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.